Research Triangle Park, North Carolina
October 16,  2001

Paradigm Genetics, Inc. (Nasdaq: PDGM) today announced the issuance of United States Patent 6,303,365, titled "Method of determining activity of 1-deoxy-D-xylulose-5-phosphate reductoisomerase and 1-deoxy-D-xylulose-5- phosphate synthase." The issued patent is for a
gene that produces a protein that is a potential herbicide target. It was discovered jointly by Paradigm and Bayer AG through the two companies' commercial partnership. 

"This patent is the first patent issued to Paradigm Genetics, and it represents the beginning of what we believe will be a very productive pipeline of valuable intellectual property resulting from our own research and our research in conjunction with our commercial partners," said Henry Nowak, Paradigm's General Counsel and Vice President of Intellectual Property. "We have more than 100 patents pending, and that number grows every week." 

"Besides showing that our research is producing concrete results, this patent also demonstrates the value we bring to our commercial partners and the level of cooperation that occurs in those partnerships," said John A. Ryals, Ph.D., CEO and President. "We have dedicated significant resources towards developing a comprehensive patent portfolio over the last several years, and our effort is now beginning to yield results. This is only the beginning, however. There's much more to come."  

Located in Research Triangle Park, NC, Paradigm Genetics, Inc. is industrializing the process of gene function discovery for four major sectors of the global economy: human health, nutrition, crop production, and industrial products. The company has designed the GeneFunction Factory(TM) - an integrated, rapid, industrial-scale laboratory through which it discovers gene function. Paradigm and its strategic partners intend to develop novel products using information developed with the GeneFunction Factory(TM). Paradigm's GeneFunction Factory(TM) is based on a state-of-the-art phenomics platform integrated with metabolic profiling and gene expression profiling technologies. The backbone of the GeneFunction Factory(TM) is the company's proprietary FunctionFinder(TM) bioinformatics system, used to collect, store, analyze and retrieve information. For more information, visit www.paradigmgenetics.com. 

Company news release
N3882